title: The effects of ErhBMP-2-/EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs.
abstract: OBJECTIVE
  The purpose was to evaluate the effect of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2)-/epigallocatechin-3-gallate (EGCG)-coated biphasic calcium phosphate (BCP) and titanium barrier membrane on dehiscence defects in dogs.
  
  
  METHODS
  In five mongrel dogs, the dehiscence bony defects around dental implants were surgically created and in total three implants were placed at edentulous ridge of which teeth had been extracted 12 weeks before. For the control group, BCP was applied to the dehiscence defect. For experimental groups, ErhBMP-2-coated BCP and ErhBMP-2-/EGCG-coated BCP were applied. The newly designed titanium barrier membrane was used to apply all the defects. The defects were evaluated histologically and histometrically after 12 weeks. The comparative statistics of the groups were obtained through Kruskal-Wallis test.
  
  
  RESULTS
  In bone-to-implant contact (BIC), bone density (BD), bone regeneration height (BRH), and bone mineralization apposition rate (BMAR), differences among groups were not found. ErhBMP-2/EGCG group appeared to have higher value. In fluorescence analysis, bone remodeling around graft material was more active in the ErhBMP-2/EGCG group.
  
  
  CONCLUSIONS
  Within the limit of this study, it is reasonable to assume that BMP-2-/EGCG-coated biphasic BCP and the newly designed titanium membrane were more beneficial in dehiscence defect healing with increased bone remodeling.
authors: Department of Conservative Dentistry, Oral Science Research Center, Yonsei University College of Dentistry, Seoul, Korea.
authors: Y S
authors: YS
authors: Shin
authors: J Y
authors: JY
authors: Seo
authors: S H
authors: SH
authors: Oh
authors: J H
authors: JH
authors: Kim
authors: S T
authors: ST
authors: Kim
authors: Y B
authors: YB
authors: Park
authors: H S
authors: HS
authors: Moon
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D018786:Bone Substitutes; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology; D015921:Dental Implants; D017267:Dental Prosthesis Design; D004285:Dogs; D016557:Guided Tissue Regeneration, Periodontal; D006882:Hydroxyapatites; D010012:Osteogenesis / Q000187:drug effects*; D011994:Recombinant Proteins / Q000494:pharmacology; D014025:Titanium; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: D055396:Bone Morphogenetic Protein 2; D018786:Bone Substitutes; D015921:Dental Implants; D006882:Hydroxyapatites; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C074950:hydroxyapatite-beta tricalcium phosphate; C499469:recombinant human bone morphogenetic protein-2; D002392:Catechin; C045651:epigallocatechin gallate; D014025:Titanium
keywords: ErhBMP-2; GBR; biphasic calcium phosphate; dehiscence defect; epigallocatechin-3-gallate; titanium barrier membrane